XPhyto Therapeutic Corporation (XPHYF) Corporate Media Kit

Recent Developments XPhyto Therapeutics Corporation A next generation bioscience company | Business Highlights Exclusive development partnership with 3a-Diagnostics GmbH Acquisition of Vektor Pharma TF GmbH Exclusive psychedelic API production partnerships Therapeutic Pipeline Transdermal - Rotigotine TDS Oral Dissolvable - CBD, THC, and CBD:THC Non-dilutive Funding Funding from German Federal Ministry of Education and Research for development of real- time ultra low-cost biosensors for high-risk pandemic threats such as influenza, swine flu and avian flu. Outlook Diagnostic Pipeline COVID-19 PCR Test launched Q2, 2021 Oral biosensors launch Q4, 2021 Psychedelic Medicine Exclusive development deal with Canadian University for industrial scale synthesis of pharmaceutical grade Mescaline. Exclusive development deal with German University for industrial scale biotech production of pharmaceutical grade Psilocybin. 12